TrialBlood2012

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.

Suzanne Lentzsch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.